Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 141 articles:
HTML format

Single Articles

    August 2022
  1. TAKADA K, Kashiwagi S, Kouhashi R, Iimori N, et al
    The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer.
    Anticancer Res. 2022;42:3937-3946.
    PubMed     Abstract available

  2. SHIMAZAKI A, Kubo M, Kurata K, Takao Y, et al
    CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.
    Anticancer Res. 2022;42:4071-4077.
    PubMed     Abstract available

  3. LIAO PA, Chu PY, Tan ZL, Hsu FT, et al
    STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer In Vivo.
    Anticancer Res. 2022;42:3807-3814.
    PubMed     Abstract available

  4. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available

  5. KITANO S, Honda A, Itoi N, Lee T, et al
    Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.
    Anticancer Res. 2022;42:3913-3919.
    PubMed     Abstract available

  6. WANG YC, Wang ZH, Yen JH, Shen YC, et al
    The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan.
    Anticancer Res. 2022;42:3799-3806.
    PubMed     Abstract available

  7. VANNI G, Pellicciaro M, Materazzo M, Melaiu O, et al
    Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
    Anticancer Res. 2022;42:3879-3888.
    PubMed     Abstract available

  8. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
    Anticancer Res. 2022;42:4179-4187.
    PubMed     Abstract available

    July 2022
  9. NOZAWA K, Takatsuka D, Endo Y, Horisawa N, et al
    Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study.
    Anticancer Res. 2022;42:3735-3742.
    PubMed     Abstract available

  10. OZAKI A, Motomura H, Tamori S, Onaga C, et al
    High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2022;42:3299-3312.
    PubMed     Abstract available

  11. SAITO Y, Takekuma Y, Takeshita T, Noguchi T, et al
    Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
    Anticancer Res. 2022;42:3693-3700.
    PubMed     Abstract available

  12. SAITO Y, Takekuma Y, Takeshita T, Sugawara M, et al
    Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens.
    Anticancer Res. 2022;42:3753-3758.
    PubMed     Abstract available

  13. SAEED MEM, Drif AI, Efferth T
    Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
    Anticancer Res. 2022;42:3483-3494.
    PubMed     Abstract available

  14. CHOI HY, Lee HJ, Moon KM, Moon DK, et al
    Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells.
    Anticancer Res. 2022;42:3445-3452.
    PubMed     Abstract available

  15. NIGUMA K, Mamishin K, Naito Y, Nomura S, et al
    Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
    Anticancer Res. 2022;42:3743-3751.
    PubMed     Abstract available

    June 2022
  16. RADES D, Narvaez CA, Dziggel L, Splettstosser L, et al
    Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer - Final Results of the Prospective Interventional RADIO-SLEEP Trial.
    Anticancer Res. 2022;42:3085-3089.
    PubMed     Abstract available

  17. ROSENKAIMER S, Sieburg T, Winter L, Mavratzas A, et al
    Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
    Anticancer Res. 2022;42:3075-3084.
    PubMed     Abstract available

  18. YEHIA ZA, Yoon J, Sayan M, Kumar S, et al
    Does the Use of BioZorb((R)) Result in Smaller Breast Seroma Volume?
    Anticancer Res. 2022;42:2961-2965.
    PubMed     Abstract available

    May 2022
  19. CHUNG Y, Kim S, Kim HS, DO SI, et al
    High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma.
    Anticancer Res. 2022;42:2753-2761.
    PubMed     Abstract available

  20. HAN M, Yamaguchi S, Onishi M, Fujii T, et al
    The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.
    Anticancer Res. 2022;42:2277-2288.
    PubMed     Abstract available

  21. TAKEMURA M, Ikemura K, Yoshinami T, Toyozumi Y, et al
    Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2022;42:2591-2598.
    PubMed     Abstract available

  22. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis - A Prospective Three-year Study.
    Anticancer Res. 2022;42:2507-2517.
    PubMed     Abstract available

  23. NISHIMURA M, Imaoka T, Daino K, Nishimura Y, et al
    Copenhagen Rats Display Dominantly Inherited Yet Non-uniform Resistance to Spontaneous, Radiation-induced, and Chemically-induced Mammary Carcinogenesis.
    Anticancer Res. 2022;42:2415-2423.
    PubMed     Abstract available

    April 2022
  24. TANAKA M, Yamashita SI, Yoshinaga Y, Enomoto Y, et al
    Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence.
    Anticancer Res. 2022;42:2079-2085.
    PubMed     Abstract available

  25. PARK HL, Yang B, Shin JE, Kim JY, et al
    Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy.
    Anticancer Res. 2022;42:2159-2165.
    PubMed     Abstract available

    March 2022
  26. KASHIWAGI S, Asano Y, Takada K, Goto W, et al
    Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Anticancer Res. 2022;42:1421-1431.
    PubMed     Abstract available

  27. OKAMOTO A, Funakoshi Y, Oe M, Takai R, et al
    Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.
    Anticancer Res. 2022;42:1199-1205.
    PubMed     Abstract available

  28. DANTAS FT, Felix-Silva PH, Angotti-Carrara HH, Dos-Reis FJC, et al
    A New Method for Obtaining Tumor Interstitial Fluid Applied to Cytokine Analysis of Breast Carcinoma Samples.
    Anticancer Res. 2022;42:1327-1332.
    PubMed     Abstract available

    February 2022
  29. SEKI H, Sakurai T, Sakurada A, Kinoshita T, et al
    Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2022;42:1099-1106.
    PubMed     Abstract available

  30. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available

  31. WAZIR U, Patani N, Heeney J, Mokbel K, et al
    Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants.
    Anticancer Res. 2022;42:1013-1018.
    PubMed     Abstract available

  32. GOTO W, Kashiwagi S, Takada K, Asano Y, et al
    Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2022;42:939-946.
    PubMed     Abstract available

  33. NIEDER C, Ressheim J, Haukland EC, Mannsaker B, et al
    Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort.
    Anticancer Res. 2022;42:923-928.
    PubMed     Abstract available

  34. COMSA S, Ceausu AR, Popescu R, Cimpean AM, et al
    Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane In Vivo Model of Breast Cancer.
    Anticancer Res. 2022;42:877-883.
    PubMed     Abstract available

  35. HO CY, Hu DW, Chen BR, Yang CC, et al
    Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer Via Activation of the Fas Pathway.
    Anticancer Res. 2022;42:845-855.
    PubMed     Abstract available

  36. GOHNO T, Hanamura T, Kurosumi M, Takei H, et al
    One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence.
    Anticancer Res. 2022;42:759-766.
    PubMed     Abstract available

  37. SONG C, Kendi AT, Lowe VJ, Lee S, et al
    The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.
    Anticancer Res. 2022;42:681-695.
    PubMed     Abstract available

  38. MOKBEL K, Mokbel K
    The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy.
    Anticancer Res. 2022;42:661-666.
    PubMed     Abstract available

    January 2022
  39. MAZAKI AI, Yamauchi K, Orita S, Inage K, et al
    Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis.
    Anticancer Res. 2022;42:581-587.
    PubMed     Abstract available

    Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
    Anticancer Res. 2022;42:565-579.
    PubMed     Abstract available

  41. HOSOYA K, Nosaka K, Sakabe T, Wakahara M, et al
    Clinical Significance of Serglycin Expression in Human Breast Cancer Patients.
    Anticancer Res. 2022;42:279-285.
    PubMed     Abstract available

  42. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available

  43. ASANO Y, Kashiwagi S, Takada K, Ishihara S, et al
    Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Anticancer Res. 2022;42:125-136.
    PubMed     Abstract available

  44. SAYAN M, Vergalasova I, Jan I, Kumar S, et al
    Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer.
    Anticancer Res. 2022;42:93-96.
    PubMed     Abstract available

  45. SAYAN M, Yehia ZA, Jan I, Gupta A, et al
    Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
    Anticancer Res. 2022;42:53-57.
    PubMed     Abstract available

  46. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
    Anticancer Res. 2022;42:311-320.
    PubMed     Abstract available

    December 2021
  47. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed     Abstract available

  48. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed     Abstract available

  49. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available

  50. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed     Abstract available

  51. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed     Abstract available

  52. NOMURA T, Kurebayashi J, Moriya T, Saito W, et al
    A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Anticancer Res. 2021;41:6191-6197.
    PubMed     Abstract available

  53. COLLERY P, Veena V, Desmaele D, Harikrishnan A, et al
    Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.
    Anticancer Res. 2021;41:5997-6001.
    PubMed     Abstract available

    November 2021
  54. TOKISAWA H, Aruga T, Honda Y, Ishiba T, et al
    Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
    Anticancer Res. 2021;41:5723-5728.
    PubMed     Abstract available

  55. PIANKA J, Gruba N, Kitowska K, Mieczkowski K, et al
    Simplified Theta-defensin [Ser(3,7,12,16)] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer.
    Anticancer Res. 2021;41:5415-5423.
    PubMed     Abstract available

  56. VANNI G, Caiazza G, Materazzo M, Storti G, et al
    Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: Alpha Randomized Controlled Trial.
    Anticancer Res. 2021;41:5667-5676.
    PubMed     Abstract available

  57. VANNI G, Pellicciaro M, Sadri A, Tacconi F, et al
    Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis.
    Anticancer Res. 2021;41:5657-5665.
    PubMed     Abstract available

    October 2021
  58. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available

  59. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed     Abstract available

  60. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed     Abstract available

  61. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
    The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Anticancer Res. 2021;41:4715-4718.
    PubMed     Abstract available

    September 2021
  62. VANNI G, Pellicciaro M, Combi F, Papi S, et al
    Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.
    Anticancer Res. 2021;41:4535-4542.
    PubMed     Abstract available

  63. WANG YC, Wang ZH, Shen TC, Chang WS, et al
    Contribution of Interleukin-12A Genotypes to Breast Cancer Risk.
    Anticancer Res. 2021;41:4387-4393.
    PubMed     Abstract available

  64. LIAO CL, Peng SF, Chen JC, Chen PY, et al
    Allyl Isothiocyanate Induces DNA Damage and Impairs DNA Repair in Human Breast Cancer MCF-7 Cells.
    Anticancer Res. 2021;41:4343-4351.
    PubMed     Abstract available

  65. YONEMITSU K, Miyasato Y, Shiota T, Shinchi Y, et al
    Soluble Factors Involved in Cancer Cell-Macrophage Interaction Promote Breast Cancer Growth.
    Anticancer Res. 2021;41:4249-4258.
    PubMed     Abstract available

  66. WATANABE J, Nakamoto S, Sugino T
    The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution.
    Anticancer Res. 2021;41:4619-4627.
    PubMed     Abstract available

  67. RIFFEL J, Kannengiesser S, Schoenberg SO, Kaiser AK, et al
    T2-weighted Imaging of the Breast at 1.5T Using Simultaneous Multi-slice Acceleration.
    Anticancer Res. 2021;41:4423-4429.
    PubMed     Abstract available

    August 2021
  68. YAMADA M, Kubo M, Yamamoto H, Yamashita N, et al
    Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Anticancer Res. 2021;41:4143-4149.
    PubMed     Abstract available

  69. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy.
    Anticancer Res. 2021;41:4133-4141.
    PubMed     Abstract available

  70. OGINO M, Fujii T, Koibuchi Y, Nakazawa Y, et al
    Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
    Anticancer Res. 2021;41:3899-3904.
    PubMed     Abstract available

  71. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available

  72. KIM H, Gim JA, Kim CY, Kim A, et al
    Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
    Anticancer Res. 2021;41:3779-3787.
    PubMed     Abstract available

    July 2021
  73. YAMANOUCHI K, Maeda S, Takei D, Koga Y, et al
    Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
    Anticancer Res. 2021;41:3625-3634.
    PubMed     Abstract available

  74. TANG A, Mooney CM, Beattie G, Cohan CM, et al
    Health Equity Within Inequity: Timing of Diagnostic Breast Cancer Care in an Underserved Medical Population.
    Anticancer Res. 2021;41:3607-3613.
    PubMed     Abstract available

  75. SUZUKI C, Yamada A, Adachi S, Shima H, et al
    Bromodomain-containing Protein 4 Is a Favourable Prognostic Factor in Breast Cancer Patients.
    Anticancer Res. 2021;41:3597-3606.
    PubMed     Abstract available

  76. RAJBONGSHI L, Noh MH, Kim YS, Hur DY, et al
    Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
    Anticancer Res. 2021;41:3449-3458.
    PubMed     Abstract available

  77. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available

  78. KIM CY, Kim YC, Oh JH, Kim MH, et al
    HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Anticancer Res. 2021;41:3409-3417.
    PubMed     Abstract available

  79. MARCHICA P, D'Arpa S, Magno S, Rossi C, et al
    Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art.
    Anticancer Res. 2021;41:3233-3246.
    PubMed     Abstract available

    June 2021
  80. KIM K, Chun M, Jin H, Jung W, et al
    Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG 19-01).
    Anticancer Res. 2021;41:3145-3152.
    PubMed     Abstract available

  81. AKAGI H, Shimada A, Chin K, Domoto H, et al
    Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient.
    Anticancer Res. 2021;41:3139-3144.
    PubMed     Abstract available

  82. MIKI M, Takao S, Konishi M, Shigeoka Y, et al
    Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer Res. 2021;41:3121-3126.
    PubMed     Abstract available

  83. KRAWCZYK N, Janowski K, Banys-Paluchowski M, Staebler A, et al
    The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2021;41:2849-2858.
    PubMed     Abstract available

  84. WALL TP, Crowley PD, Buggy DJ
    The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro.
    Anticancer Res. 2021;41:2835-2840.
    PubMed     Abstract available

  85. OHLINGER R, Alwafai Z, Paepke S, Zygmunt M, et al
    Patient Quality of Life After Subpectoral Implant-based Breast Reconstruction With Synthetic or Biological Materials.
    Anticancer Res. 2021;41:3075-3082.
    PubMed     Abstract available

    May 2021
  86. ORSARIA P, Grasso A, Ippolito E, Pantano F, et al
    Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Anticancer Res. 2021;41:2697-2709.
    PubMed     Abstract available

  87. VANNI G, Pellicciaro M, Materazzo M, Pedini D, et al
    Advanced Stages and Increased Need for Adjuvant Treatments in Breast Cancer Patients: The Effect of the One-year COVID-19 Pandemic.
    Anticancer Res. 2021;41:2689-2696.
    PubMed     Abstract available

  88. RADES D, Narvaez CA, Dziggel L, Tvilsted S, et al
    Sleep Disorders in Patients With Breast Cancer Prior to a Course of Radiotherapy - Prevalence and Risk Factors.
    Anticancer Res. 2021;41:2489-2494.
    PubMed     Abstract available

  89. CHEN KY, Chien WC, Liao JM, Tsai CW, et al
    Contribution of Interleukin-10 Genotype to Triple Negative Breast Cancer Risk.
    Anticancer Res. 2021;41:2451-2457.
    PubMed     Abstract available

  90. ALAAELDIN R, Abuo-Rahma GEA, Zhao QL, Fathy M, et al
    Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-beta/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells.
    Anticancer Res. 2021;41:2383-2395.
    PubMed     Abstract available

  91. JINIH M, Wang JH, Pfirrmann RW, O'Leary DP, et al
    Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2021;41:2247-2256.
    PubMed     Abstract available

  92. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available

    April 2021
  93. HAYASHI K, Tamura M, Nagasaki E, Yoshii Y, et al
    A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.
    Anticancer Res. 2021;41:2193-2195.
    PubMed     Abstract available

  94. SASAKI R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, et al
    Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:2133-2140.
    PubMed     Abstract available

  95. VANNI G, Materazzo M, Pellicciaro M, Amir S, et al
    Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study.
    Anticancer Res. 2021;41:2123-2132.
    PubMed     Abstract available

  96. JOSEPH WJ, Bustos SS, Losee JE, Rubin JP, et al
    The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.
    Anticancer Res. 2021;41:1903-1908.
    PubMed     Abstract available

  97. RIGAKOS G, Razis E, Koliou GA, Oikonomopoulos G, et al
    Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Anticancer Res. 2021;41:1793-1802.
    PubMed     Abstract available

  98. OHLINGER R, Nawroth F, Kohlmann T, Alwafai Z, et al
    Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction.
    Anticancer Res. 2021;41:2017-2024.
    PubMed     Abstract available

  99. ZWICKER F, Hoefel S, Kirchner C, Huber PE, et al
    Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge.
    Anticancer Res. 2021;41:1909-1920.
    PubMed     Abstract available

    March 2021
  100. YAMAMOTO S, Narui K, Ishikawa T, Adachi S, et al
    First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
    Anticancer Res. 2021;41:1671-1676.
    PubMed     Abstract available

  101. FERINI G, Molino L, Tripoli A, Valenti V, et al
    Anatomical Predictors of Dosimetric Advantages for Deep-inspiration-breath-hold 3D-conformal Radiotherapy Among Women With Left Breast Cancer.
    Anticancer Res. 2021;41:1529-1538.
    PubMed     Abstract available

  102. KRAJNAK S, Loewe A, Battista MJ, Hasenburg A, et al
    The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
    Anticancer Res. 2021;41:1243-1250.
    PubMed     Abstract available

  103. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

    February 2021
  104. INOUE S, Kawaida H, Saito R, Nakayama Y, et al
    Clinical Significance of Past History of Breast Cancer Screening for the Prognosis of Triple Negative Breast Cancer.
    Anticancer Res. 2021;41:1077-1082.
    PubMed     Abstract available

  105. YAMADA A, Nakazawa K, Akazawa K, Narui K, et al
    Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
    Anticancer Res. 2021;41:1063-1068.
    PubMed     Abstract available

  106. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:949-954.
    PubMed     Abstract available

  107. OKAZAKI M, Mogushi K, Denda-Nagai K, Fujihira H, et al
    Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:845-858.
    PubMed     Abstract available

  108. RAICA M, Ceausu AR, Cimpean AM, ComSa S, et al
    Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:795-802.
    PubMed     Abstract available

  109. SHARIF-ASKARI FS, Al-Khayyal N, Talaat I, Sharif-Askari NS, et al
    Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates With Early Tumorigenesis in Breast Cancer.
    Anticancer Res. 2021;41:739-745.
    PubMed     Abstract available

  110. PAPADAKI MA, Aggouraki D, Vetsika EK, Xenidis N, et al
    Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Anticancer Res. 2021;41:661-670.
    PubMed     Abstract available

  111. UNGER J, Rutkowski R, Kohlmann T, Paepke S, et al
    Potential Risk Factors Influencing the Formation of Postoperative Seroma After Breast Surgery - A Prospective Study.
    Anticancer Res. 2021;41:859-867.
    PubMed     Abstract available

  112. WALKER RR, Gallegos KM, Bratton MR, Lemieux KP, et al
    Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
    Anticancer Res. 2021;41:583-599.
    PubMed     Abstract available

    January 2021
  113. SCHMIDT M, KUmmel S, Ruf-Doerdelmann A, Distelrath A, et al
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin((R))) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Anticancer Res. 2021;41:485-496.
    PubMed     Abstract available

  114. OBA T, Maeno K, Ono M, Ito T, et al
    Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Anticancer Res. 2021;41:445-452.
    PubMed     Abstract available

  115. SAGARA M, Miyamoto S, Itoh S, Soda Y, et al
    Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Anticancer Res. 2021;41:81-89.
    PubMed     Abstract available

  116. CHOI YE, Sung K, Dong KS, Kim HJ, et al
    Dosimetric Impact of Respiratory Motion During Breast Intensity-modulated Radiation Therapy Using Four-dimensional Dose Calculations.
    Anticancer Res. 2021;41:417-427.
    PubMed     Abstract available

  117. IBRAGIMOVA MK, Tsyganov MM, Pevzner AM, Litviakov NV, et al
    Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8.
    Anticancer Res. 2021;41:187-195.
    PubMed     Abstract available

  118. ONAGA C, Tamori S, Motomura H, Ozaki A, et al
    High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
    Anticancer Res. 2021;41:43-54.
    PubMed     Abstract available

    December 2020
  119. VANNI G, Tazzioli G, Pellicciaro M, Materazzo M, et al
    Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
    Anticancer Res. 2020;40:7119-7125.
    PubMed     Abstract available

  120. MACAIONE I, Galvano A, Graceffa G, Lupo S, et al
    Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer.
    Anticancer Res. 2020;40:7083-7088.
    PubMed     Abstract available

  121. TSAI CL, Tsai CW, Chang WS, Su CH, et al
    Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility.
    Anticancer Res. 2020;40:6743-6749.
    PubMed     Abstract available

  122. YAMADA A, Suzuki C, Shima H, Kida K, et al
    Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis.
    Anticancer Res. 2020;40:6733-6742.
    PubMed     Abstract available

  123. NIWA Y, Asano M, Nakagawa T, France D, et al
    Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Anticancer Res. 2020;40:6699-6712.
    PubMed     Abstract available

  124. ANAYA-EUGENIO GD, Eggers NA, Ren Y, Rivera-ChAvez J, et al
    Apoptosis Induced by (+)-Betulin Through NF-kappaB Inhibition in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:6637-6647.
    PubMed     Abstract available

  125. ROBINSON AGJ, Kanaan YM, Copeland RL
    Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:6623-6635.
    PubMed     Abstract available

    November 2020
  126. NUZZO M, Ursini LA, Patani F, Rosa C, et al
    Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group.
    Anticancer Res. 2020;40:6505-6511.
    PubMed     Abstract available

  127. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    PubMed     Abstract available

  128. AUGUSTINE TN, Duarte R, Candy GP
    Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model.
    Anticancer Res. 2020;40:6179-6193.
    PubMed     Abstract available

  129. SHIMODA M, Kim SJ, Tokuda Y, Sota Y, et al
    Effect of Computer-aided Detection System Use on the Duration of MRI-guided Biopsy of the Breast.
    Anticancer Res. 2020;40:6437-6441.
    PubMed     Abstract available

  130. STOPE MB, Benouahi R, Sander C, Haralambiev L, et al
    Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device.
    Anticancer Res. 2020;40:6205-6212.
    PubMed     Abstract available

    October 2020
  131. SHINDEN Y, Nagata A, Nomoto Y, Saho H, et al
    Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence.
    Anticancer Res. 2020;40:5739-5742.
    PubMed     Abstract available

  132. YENILMEZ EN, Genc D, Farooqi AA, Tunoglu S, et al
    Mesenchymal Stem Cells Combined With IFNgamma Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL.
    Anticancer Res. 2020;40:5641-5647.
    PubMed     Abstract available

  133. MARGAN MM, Cimpean AM, Ceausu AR, Raica M, et al
    Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
    Anticancer Res. 2020;40:5557-5566.
    PubMed     Abstract available

  134. LI CL, Huang CW, Ko CJ, Fang SY, et al
    Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction.
    Anticancer Res. 2020;40:5529-5538.
    PubMed     Abstract available

  135. SCATOZZA F, D'Amore A, Fontanella RA, DE Cesaris P, et al
    Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1alpha.
    Anticancer Res. 2020;40:5379-5391.
    PubMed     Abstract available

  136. WAZIR U, Mokbel K
    De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Anticancer Res. 2020;40:5351-5354.
    PubMed     Abstract available

  137. KIM SW, Kim HS, Na K
    Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
    Anticancer Res. 2020;40:5925-5932.
    PubMed     Abstract available

  138. PARK JH, Ahn JH, Kim JE, Jung KH, et al
    Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Anticancer Res. 2020;40:5883-5893.
    PubMed     Abstract available

  139. YILDIRIM E, Bektas S, Gundogar O, Findik D, et al
    The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2020;40:5649-5657.
    PubMed     Abstract available

  140. PERNICONE N, Peretz L, Grinshpon S, Listovsky T, et al
    MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
    Anticancer Res. 2020;40:5471-5480.
    PubMed     Abstract available

    September 2020
  141. NASIR UM, Mozeika AM, Sayan M, Jan I, et al
    Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
    Anticancer Res. 2020;40:5291-5294.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.